The stock's fall snapped a two-day winning streak.

EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

This was the stock's second consecutive day of gains.

Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has ...

Ocugen (OCGN) announced that the U.S. FDA has reviewed the company’s Investigational New Drug application and it is in effect. This is a ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...

At close: 14 November at 4:00 pm GMT-5 ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...